An estimated 78,000 cancer patients are not properly tested each year in the United States alone and are possibly not getting access to potentially lifesaving medications. The recent collaboration between Diaceutics, Intel and Lenovo combining Lenovo hardware and Intel® Xeon® Scalable processors for workstations enables Diaceutics to leverage their vast proprietary database of patient testing data in a revolutionary way. Using artificial intelligence (AI) to see whether patients can be grouped according to diagnostic test information, the company is hopeful that this data can help identify ways to improve diagnosis, treatment and outcomes for patients with similar characteristics. The collaboration delivers the computing power needed to add new machine learning capabilities on top of today’s big data analysis. Find out more about what this collaboration means for patient care: https://www.diaceutics.com/2018/03/05/diaceutics-intel-lenovo-advance-patient-care-using-ai-workstations-powered-intel-xeon-scalable-processors/